Eravacycline: A New Weapon Against Complicated Intra-Abdominal Infections?

In a phase III trial, this novel synthetic fluorocycline antibiotic was noninferior to ertapenem.

Eravacycline, in development to address the urgent need for new antimicrobial agents, is a synthetic tetracycline analogue designed to be resistant to antibiotic efflux pumps and active against microorganisms with ribosomally mediated tetracycline resistance. Now, in a manufacturer-supported, international, multicenter, phase III trial, researchers show that eravacycline is noninferior to ertapenem for complicated intra-abdominal infections.

In all, 541 patients were enrolled, with 270 receiving eravacycline (1 mg/kg every 12 hours intravenously) and 271 receiving ertapenem (1 g every 24 hours intravenously). The most common infections were intra-abdominal abscess (42%) and peritonitis (33%); complicated appendicitis occurred in 31% of parti…

Reviewing Author

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Eravacycline: A New Weapon Against Complicated Intra-Abdominal Infections?

Topics

Reviewing Author